Recursion Pharmaceuticals, Inc. (RXRX)

US — Healthcare Sector

Peers: ZURA ELEV VERV SANA RLAY RPTX

Automate Your Wheel Strategy on RXRX

With Tiblio's Option Bot, you can configure your own wheel strategy including RXRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol RXRX
Rev/Share 0.1547
Book/Share 2.2023
PB 2.4883
Debt/Equity 0.0958
CurrentRatio 3.5797
ROIC -0.5607

MktCap 2330539880.0
FreeCF/Share -0.9374
PFCF -5.9571
PE -3.5243
Debt/Assets 0.0676
DivYield 0
ROE -0.7607

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 1
P/B Score 3
D/E Score 3

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Resumed	RXRX	Morgan Stanley	--	Equal Weight	--	$5	July 3, 2025

News

Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?

RXRX
Published: February 21, 2025 by: MarketBeat
Sentiment: Neutral

Recursion Pharmaceuticals' NASDAQ: RXRX stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence (AI) chip giant NVIDIA NASDAQ: NVDA. A recent SEC filing showed NVIDIA reshuffling its AI investment portfolio, and while it trimmed its holdings in several AI ventures, it notably maintained its stake in Recursion Pharmaceuticals.

image for news Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?

Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why

RXRX
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Neutral

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $8.50, indicating a +1.92% shift from the previous trading day.

image for news Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

RXRX
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Neutral

Recursion Pharmaceuticals (RXRX) closed at $7.66 in the latest trading session, marking a +0.13% move from the prior day.

image for news Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

1
2 (current)

About Recursion Pharmaceuticals, Inc. (RXRX)

IPO Date 2021-04-16
Website https://www.recursion.com
Industry Biotechnology
CEO Christopher C. Gibson
Employees 800

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.